HonCode

Go Back   HER2 Support Group Forums > Breast Cancer Meeting Highlights
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Breast Cancer Meeting Highlights News fro recent ASCO and San Antonio Meetings

Reply
 
Thread Tools Display Modes
Old 05-19-2014, 10:10 AM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post An immune-related signature for prediction of risk of late recurrences beyond prolife

An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer.

Abstract No:
530
Attend this session at the
2014 ASCO Annual Meeting!


Session: Breast Cancer - HER2/ER
Type: Poster Highlights Session
Time 1: Sunday June 1, 8:00 AM to 11:00 AM
Location 1: E354b

Time 2: Sunday June 1, 11:30 AM to 12:45 PM
Location 2: E Arie Crown Theater
Personalize your Meeting experience with a suggested or customized itinerary!

Author(s): Giampaolo Bianchini, Gabriella Rossi, Maurizio Callari, Takayuki Iwamoto, Eugenia Galeota, Thomas Karn, Catherine Margaret Kelly, Milvia Zambetti, Libero Santarpia, Lajos Pusztai, Luca Gianni; San Raffaele Hospital, Milan, Italy; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Okayama University Hospital, Okayama, Japan; Department of Obstetrics and Gynecology, Goethe University, Frankfurt, Germany; Department of Medical Oncology, Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Center Humanitas, Milan, Italy; Yale School of Medicine, New Haven, CT
Abstract Disclosures

Abstract:

Background: In ER+ tumors, a dentritic metagene (DM) predicts for lower risk of relapse (Bianchini G JCO 2010; Bianchini G ASCO 2012). We investigated if other immune metagenes provided additional prognostic information and their involvement in early and late (after 5 years) relapses. Methods: We evaluated public available Affymetrix-based gene expression profiles from ER+ untreated (n=599) and adjuvant tamoxifen (TAM)-treated pts (n=683). Four previously defined immune metagenes were evaluated: CD8, MHC1, STAT1 and interferon inducible (IF.I) (Gianni L SABCS 2012). Multivariate analyses were adjusted by estrogen-related genes, proliferation (Bianchini G Breast Cancer Res 2013) and HER2 status. Median cut-off points were used to define low and high expression groups. Outcome was assessed according to distant relapse. Results: In untreated breast cancer, adjusting for other markers only IF.I metagene retained independent prognostic value [HR 1.19 (1.00-1.41), p=0.043], with higher risk for higher expression value. This effect was driven by its prognostic value in the late period [HR 1.50 (0.99-2.28), p=0.057]. Low and high expression groups of DM and IF.I were combined. The lowDM/highIF.I group had a higher risk of recurrences in the overall period [HR 3.68 (1.96-6.91), p<0.0001], with a similar trend in the late period [HR 2.98 (0.85-10.5), p=0.08]. In tamoxifen treated patients, adjusting for other markers, IF.I was confirmed as prognostic in the overall period [HR 1.25 (1.05-1.49), p=0.01] with an even stronger time varying effect [late period: HR 1.51 (1.14-2.01), p=0.004 and early period: HR 1.12 (0.90-1.39), p=0.29]. From 5 to 10 years, the lowDM/highIF.I group had the highest risk [HR 7.26 (1.78-33.9), p=0.006] with a corresponding relapse rate of 22.8% compared to 3% in the highDM/lowIF group. Conclusions: In ER+ breast cancer, high expression of interferon inducible-related genes predicts for higher risk of late recurrences in untreated and tamoxifen-treated patients. Immune related-functions contribute to tumor dormancy and late relapses. Assessment of immune markers might contribute in tailoring extended adjuvant endocrine treatment.
'lizbeth is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 04:21 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2019, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter